SH105 successful FDA Pre-IND meeting

Delighted to announce that we have completed a successful pre-IND meeting with FDA on our oncology product SH105. The FDA’s prompt and definitive response confirms our clinical and regulatory strategy and aligns with our plan to accelerate the filling of our NDA. This positive outcome strengthens our efforts to bring SH105 to market benefiting women suffering from breast and ovarian cancer. A significant milestone on Shorla Pharma’s journey of bringing innovative oncology therapies to market.

Leave a Reply

Your email address will not be published. Required fields are marked *